Please login to the form below

Not currently logged in
Email:
Password:

Xolair

This page shows the latest Xolair news and features for those working in and with pharma, biotech and healthcare.

AZ prices severe asthma drug Fasenra below competition

AZ prices severe asthma drug Fasenra below competition

Along with Nucala and Cinqair, severe asthma patients can also be treated with Novartis’older drug Xolair (omalizumab), although that is indicated for allergic asthma and doesn’t specifically address eosinophilic

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics